A phase I trial of ramucirumab, a human monoclonal antibody against the vascular endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors (NCT02564198). (cancerresearch.org)
The Phase 1 open - label, multicenter, dose escalation study of mRNA - 2416 is designed to determine the safety and tolerability of escalating iTu doses of mRNA - 2416 in patients with relapsed / refractory solid tumor malignancies or lymphoma, and define the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) and schedule for iTu injections of mRNA - 2416. (modernatx.com)
The multikinase angiogenesis inhibitor pazopanib was well tolerated and exhibited some responses in pediatric patients with soft - tissue sarcomas and other refractory solid tumors in a phase I trial. (cancernetwork.com)